What Now for the Endovascular Community After the Paclitaxel Mortality Meta-Analysis: Can Sirolimus Replace Paclitaxel in the Peripheral Vasculature?

Abstract

Keywords

drug-coated balloon drug-eluting stent drug-eluting technology femoropopliteal segment mortality paclitaxel sirolimus superficial femoral artery

Get full access to this article

View all access options for this article.

References

Katsanos

Spiliopoulos

Kitrou

, et al. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: A systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018;7:e011245.

Tepe

Schnorr

Albrecht

, et al. Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5-year follow-up of the THUNDER trial. JACC Cardiovasc Interv. 2015;8:102–108.

Dake

Ansel

Jaff

, et al. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX randomized trial. Circulation. 2016;133:1472–1483.

Salisbury

Vilain

, et al. Cost-effectiveness of endovascular femoropopliteal intervention using drug-coated balloons versus standard percutaneous transluminal angioplasty: Results from the IN.PACT SFA II trial. JACC Cardiovasc Interv. 2016;9:2343–2352.

Caradu

Lakhlifi

Colacchio

, et al. Systematic review and updated meta-analysis of the use of drug-coated balloon angioplasty versus plain old balloon angioplasty for femoropopliteal arterial disease. J Vasc Surg. 2019;70:981–995.e10.

Aboyans

Ricco

Bartelink

MEL

, et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries endorsed by: The European Stroke Organization (ESO), the task force for the diagnosis and treatment of peripheral arterial diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39:763–816.

Feldman

Armstrong

Aronow

, et al. SCAI consensus guidelines for device selection in femoral-popliteal arterial interventions. Catheter Cardiovasc Interv. 2018;92:124–140.

Holden

Varcoe

Jaff

, et al. Paclitaxel and mortality: the dose argument is critical. J Endovasc Ther. 2019;26:467–470.

Katsuki

Takahara

Soga

, et al. Mortality risk following application of a paclitaxel-coated stent in femoropopliteal lesions. J Endovasc Ther. 2019;26:563–569.

10.

Schneider

Laird

Doros

, et al. Mortality not correlated with paclitaxel exposure: an independent patient-level meta-analysis of a drug-coated balloon. J Am Coll Cardiol. 2019;73:2550–2563.

11.

Takahara

Iida

Soga

, et al. Mortality risk of femoropopliteal paclitaxel-coated devices remains inconclusive. Cardiovasc Interv Ther. 2019;34:194–195.

12.

Secemsky

Kundi

Weinberg

, et al. Association of survival with femoropopliteal artery revascularization with drug-coated devices. JAMA Cardiol. 2019;4:332–340.

13.

Fanelli

Cortese

Zeller

. Use of paclitaxel-eluting technologies in the femoropopliteal segment under scrutiny over possible link to late all-cause mortality: time to panic or an opportunity to resurge? [Editorial] J Endovasc Ther. 2019;26:41–43.

14.

Zeller

Noory

Beschorner

, et al. Outstanding effectiveness of paclitaxel-based technologies for the treatment of femoropopliteal artery occlusive disease on the potential expense of increased late all-cause mortality? No reason to panic. Vasa. 2019;48:109–111.

15.

Rowinsky

Donehower

. Paclitaxel (taxol). N Engl J Med. 1995;332:1004–1014.

16.

August 7, 2019 Update: Treatment of peripheral arterial disease with paclitaxel-coated balloons and paclitaxel-eluting stents potentially associated with increased mortality—letter to health care providers. Available at https://www.fda.gov/medical-devices/letters-health-care-providers/august-7-2019-update-treatment-peripheral-arterial-disease-paclitaxel-coated-balloons-and-paclitaxel. 2019. Accessed September 16, 2019.

17.

MHRA issues medical device alert for paclitaxel use in the UK. Available at: https://vascularnews.com/medical-device-alert-paclitaxel/. 2019. Accessed August 3. 2019.

18.

Ali

Abdul Kader

Wan Ahmad

, et al. Treatment of coronary drug-eluting stent restenosis by a sirolimus- or paclitaxel-coated balloon. JACC Cardiovasc Interv. 2019;12:558–566.

19.

Lemos

Farooq

Takimura

, et al. Emerging technologies: Polymer-free phospholipid encapsulated sirolimus nanocarriers for the controlled release of drug from a stent-plus-balloon or a stand-alone balloon catheter. EuroIntervention. 2013;9:148–156.

20.

Dani

Shah

Sojitra

, et al. A novel nanocarrier sirolimus-coated balloon for coronary interventions: 12-month data from the Nanolute registry. Cardiovasc Revasc Med. 2019;20:235–240.

21.

FDA grants breakthrough nod to Concept Medical for below-the-knee use of MagicTouch DCB. https://www.drugdeliverybusiness.com/fda-grants-breakthrough-nod-to-concept-medical-for-below-the-knee-use-of-magictouch-dcb/. 2019. Accessed August 3. 2019.

22.

Med Alliance’s SELUTION FIM study achieves primary endpoint. https://evtoday.com/2018/01/31/med-alliances-selution-fim-study-achieves-primary-endpoint. 2018. Accessed August 3. 2019.

23.

Zeller

. First report of the SELUTION trial: 6-month outcomes of a novel sirolimus coated DCB technology evaluated in the SFA. Paper presented at: LINC; January 31, 2018; Leipzig, Germany.

24.

Cortese

Silva Orrego

Agostoni

, et al. Effect of drug-coated balloons in native coronary artery disease left with a dissection. JACC Cardiovasc Interv. 2015;8:2003–2009.

25.

Diamantopoulos

Gupta

Zayed

, et al. Paclitaxel-coated balloons and aneurysm formation in peripheral vessels. J Vasc Surg. 2015;62(5):1320–1322.